The role of β-adrenoceptor signaling in skeletal muscle: Therapeutic implications for muscle wasting disorders

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 12, Issue 6, 2009, Pages 601-606

  Koopman, René ^b   Ryall, James G ^c   Church, Jarrod E ^a   Lynch, Gordon S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CLENBUTEROL; FENOTEROL; FORMOTEROL; RACTOPAMINE;

BLOOD FLOW; CARDIOVASCULAR SYMPTOM; DRUG MEGADOSE; HUMAN; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE GROWTH; MUSCLE MASS; NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADRENERGIC AGENTS; ANIMALS; CACHEXIA; HUMANS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PROTEINS; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; WASTING SYNDROME;

ANIMALIA;

EID: 70350129056     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3283318a25     Document Type: Review

References (81)

1. Carbo N, Lopez-Soriano J, Tarrago T. Comparative effects of p2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett 1997; 115:113-118.
2. Lynch GS, Schertzer JD, Ryall JG. Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 2007; 113:461-487.
3. Ryall JG, Lynch GS. The potential and the pitfalls of p-adrenoceptor agonists for the management of skeletal muscle wasting. Pharmacol Ther 2008; 120:219-232.
4. Lynch GS, Ryall JG. Role of p-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008; 88:729-767.
5. Dargelos E, Poussard S, Brule C, et al. Calcium-dependent proteolytic system and muscle dysfunctions: a possible role of calpains in sarcopenia. Biochimie 2008; 90:359-368.
6. Attaix D, Ventadour S, Codran A, et al. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 2005; 41:173-186.
7. Ventadour S, Attaix D. Mechanisms of skeletal muscle atrophy. Curr Opin Rheumatol 2006; 18:631-635.
8. Argiles JM, Lopez-Soriano FJ, Busquets S. Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int J Biochem Cell Biol 2008; 40:1674-1678.
9. Tisdale MJ. Is there a common mechanism linking muscle wasting in various disease types? Curr Opin Support Palliat Care 2007; 1:287-292.
10. Navegantes LC, Resano NM, Migliorini RH, Kettelhut IC. Catecholamines inhibit Ca2+-dependent proteolysis in rat skeletal muscle through p2-adre-noceptors and cAMP. Am J Physiol Endocrinol Metab 2001; 281:E449-E454.
11. Navegantes LC, Migliorini RH, Kettelhut IC. Adrenergic control of protein metabolism in skeletal muscle. Curr Opin Clin Nutr Metab Care 2002; 5:281-286.
12. Costelli P, Reffo P, Penna F, et al. Ca2+-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005; 37:2134-2146.
13. Busquets S, Figueras MT, Fuster G, et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004; 64:6725-6731.
14. HigginsJA, LasslettYV, Bardsley RG, Buttery PJ. The relation between dietary restriction or clenbuterol (a selective p2 agonist) treatment on muscle growth and calpain proteinase (EC 3.4.22.17) and calpastatin activities in lambs. Br J Nutr 1988; 60:645-652.
15. Forsberg NE, Ilian MA, Ali-Bar A, et al. Effects of cimaterol on rabbit growth and myofibrillar protein degradation and on calcium-dependent proteinase and calpastatin activities in skeletal muscle. J Anim Sci 1989; 67:3313-3321.
16. Parr T, Bardsley RG, Gilmour RS, Buttery PJ. Changes in calpain and calpastatin mRNA induced by p-adrenergic stimulation of bovine skeletal muscle. Eur J Biochem 1992; 208:333-339.
17. Hawkins C, Xu A, Narayanan N. Comparison of the effects of the membrane-associated Ca2+/calmodulin-dependent protein kinase on Ca2+-ATPase function in cardiac and slow-twitch skeletal muscle sarcoplasmic reticulum. Mol Cell Biochem 1995; 142:131-138.
18. Reiken S, Lacampagne A, Zhou H, et al. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J Cell Biol 2003; 160:919-928.
19. Sensky PL, Jewell KK, Ryan KJ, et al. Effect of anabolic agents on calpastatin promoters in porcine skeletal muscle and their responsiveness to cyclic adenosine monophosphate-and calcium-related stimuli. J Anim Sci 2006; 84:2973-2982.
20. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14:395-403.
21. Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligaseatrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117: 3940-3951.
22. Lang CH, Huber D, Frost RA. Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. Am J Physiol Regul Integr Comp Physiol 2007; 292:R328-336.
23. Costelli P, Garcia-Martinez C, Llovera M, et al. Muscle protein waste in tumor-bearing rats is effectively antagonized by a b2-adrenergic agonist (clenbuter-ol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 1995; 95:2367-2372.
24. Harcourt LJ, Schertzer JD, Ryall JG, Lynch GS. Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromuscul Disord 2007; 17:47-55.
25. Kline WO, Panaro FJ, Yang H, BodineSC. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J Appl Physiol 2007; 102:740-747.
26. Yimlamai T, Dodd SL, Borst SE, ParkS. Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. J Appl Physiol 2005; 99:71-80.
27. Pearen MA, Ryall JG, Maxwell MA, et al. The orphan nuclear receptor, NOR-1, is a target of b-adrenergic signaling in skeletal muscle. Endocrinology 2006; 147:5217-5227.
28. Berdeaux R, Goebel N, Banaszynski L, et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med 2007; 13:597-603.
29. Pearen MA, Myers SA, Raichur S, et al. The orphan nuclear receptor, NOR-1, a target of b-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 2008; 149:2853-2865
30. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003; 5:87-90.
31. Frost RA, Lang CH. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J Appl Physiol 2007; 103:378-387.
32. Sneddon AA, Delday MI, Steven J, Maltin CA. Elevated IGF-II mRNA and phosphorylation of 4E-BP1 and p70S6k in muscle showing clenbuterol-induced anabolism. Am J Physiol Endocrinol Metab 2001; 281:E676-682.
33. Akutsu S, Shimada A, Yamane A. Transforming growth factor bs are upre-gulated in the rat masseter muscle hypertrophied by clenbuterol, a b2 adrenergic agonist. Br J Pharmacol 2006; 147:412-421.
34. Buckingham M, Bajard L, Chang T, et al. The formation of skeletal muscle: from somite to limb. J Anat 2003; 202:59-68.
35. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004; 84:209-238.
36. Kim MO, NaSI, Lee MY, et al. Epinephrine increases DNA synthesis via ERK1/2s through cAMP, Ca2+/PKC, and PI3K/Akt signaling pathways in mouse embryonic stem cells. J Cell Biochem 2008; 104:1407-1420.
37. Shappell NW, Feil VJ, Smith DJ, et al. Response of C2C12 mouse and turkey skeletal muscle cells to the b-adrenergic agonist ractopamine. J Anim Sci 2000; 78:699-708.
38. Spurlock DM, McDaneld TG, McIntyre LM. Changes in skeletal muscle gene expression following clenbuterol administration. BMC Genomics 2006; 7:320.
39. Ryall JG, Gregorevic P, Plant DR, et al. b2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol 2002; 283:R1386-1394.
40. Ryall JG, Plant DR, Gregorevic P, et al. b2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol 2004; 555:175-188.
41. Ryall JG, Schertzer JD, Lynch GS. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. J Gerontol A Biol Sci Med Sci 2007; 62:813-823.
42. Lynch GS, Schertzer JD, Ryall JG. Anabolic agents for improving muscle regeneration and function after injury. Clin Exp Pharm Physiol 2008; 35:852-858.
43. Houmard JA, Weidner ML, Gavigan KE, et al. Fiber type and citrate synthase activity in the human gastrocnemius and vastus lateralis with aging. J Appl Physiol 1998; 85:1337-1341.
44. Geiger PC, Cody MJ, Macken RL, et al. Mechanisms underlying increased force generation by rat diaphragm muscle fibers during development. J Appl Physiol 2001; 90:380-388.
45. Beitzel F, Gregorevic P, Ryall JG, et al. b2-Adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol 2004; 96:1385-1392.
46. Beitzel F, Sillence MN, Lynch GS. b-Adrenoceptor signaling in regenerating skeletal muscle after b-agonist administration. Am J Physiol Endocrinol Metab 2007; 293:E932-E940.
47. Ryall JG, Schertzer JD, Alabakis TM, et al. Intramuscular b2-agonist admin-istration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury. J Appl Physiol 2008; 105:165-172.
48. Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a b2-receptor agonist. Am J Physiol 1988; 254:E726-E732.
49. Handschin C, Chin S, Li P, et al. Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1a muscle-specific knock-out animals. J Biol Chem 2007; 282:30014-30021.
50. Oh M, Rybkin II, Copeland V, et al. Calcineurin is necessary for the maintenance but not embryonic development of slow muscle fibers. Mol Cell Biol 2005; 25:6629-6638.
51. Kim MS, Fielitz J, McAnallyJ, et al. Protein kinase D1 stimulates MEF2 activity in skeletal muscle and enhances muscle performance. Mol Cell Biol 2008; 28:3600-3609.
52. Grifone R, Laclef C, Spitz F, et al. Six1 and Eya1 expression can reprogram adult muscle from the slow-twitch phenotype into the fast-twitch phenotype. Mol Cell Biol 2004; 24:6253-6267.
53. Sillence MN. Technologies for the control of fat and lean deposition in livestock. Vet J 2004; 167:242-257.
54. Lafontan M, Berlan M, Prud'Hon M. b adrenergic agonists. Mechanisms of action: lipid mobilization and anabolism. Reprod Nutr Dev 1988; 28:61-84.
55. Philipson LH. b-Agonists and metabolism. J Allergy Clin Immunol 2002; 110 (6 Suppl):S313-S317.
56. Pan SJ, Hancock J, Ding Z, et al. Effects of clenbuterol on insulin resistance in conscious obese Zucker rats. Am J Physiol Endocrinol Metab 2001; 280:E554-561.
57. Jost P, Fasshauer M, Kahn CR, et al. Atypical b-adrenergic effects on insulin signaling and action in b3-adrenoceptor-deficient brown adipocytes. Am J Physiol Endocrinol Metab 2002; 283:E146-E153.
58. Erraji-Benchekroun L, Couton D, Postic C, et al. Overexpression of b2-adrenergic receptors in mouse liver alters the expression of gluconeogenic and glycolytic enzymes. Am J Physiol Endocrinol Metab 2005; 288:E715-722.
59. Holm C. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem Soc Trans 2003; 31:1120-1124. (Pubitemid 38030921)
60. Jocken JW, Blaak EE. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol Behav 2008; 94:219-230.
61. Jocken JW, Blaak EE, Schiffelers S, et al. Association of a b2 adrenoceptor (ADRB2) gene variant with a blunted in vivo lipolysis and fat oxidation. Int J Obes 2007; 31:813-819.
62. Jocken JW, Blaak EE, van der Kallen CJ, et al. Blunted b-adrenoceptor-mediated fat oxidation in overweight subjects: a role for the hormone-sensitive lipase gene. Metabolism 2008; 57:326-332.
63. Fleury C, Neverova M, Collins S, et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 1997; 15:269-272.
64. Samec S, Seydoux J, Dulloo AG. Poststarvation gene expression of skeletal muscle uncoupling protein 2 and uncoupling protein 3 in response to dietary fat levels and fatty acid composition: a link with insulin resistance. Diabetes 1999; 48:436-441.
65. Pellegrino MA, D'Antona G, Bortolotto S, et al. Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice. Exp Physiol 2004; 89:89-100.
66. Blaak EE, van Baak MA, Kemerink GJ, et al. p-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 1995; 44:183-187.
67. Byrem TM, Beermann DH, Robinson TF. The p-agonist cimaterol directly enhances chronic protein accretion in skeletal muscle. J Anim Sci 1998; 76:988-998.
68. Mark AL, Abboud FM, Schmid PG, et al. Differences in direct effects of adrenergic stimuli on coronary, cutaneous and muscular vessels. J Clin Invest 1971; 51:279-287.
69. Rothwell NJ, Stock MJ, Sudera DK. Changes in tissue blood flow and p-receptor density of skeletal muscle in rats treated with the p2-adrenoceptor agonist clenbuterol. Br J Pharm 1987; 90:601-607.
70. Mersmann HJ. Acute changes in blood flow in pigs infused with p-adrenergic agonists. J Anim Sci 1989; 67:2913-2920.
71. Jones SW, Baker DJ, Gardiner SM, et al. The effect of the p2-adrenoceptor agonist prodrug BRL-47672 on cardiovascular function, skeletal muscle myosin heavy chain and MyoD expression in the rat. J Pharmacol Exp Ther 2004; 311:1225-1231.
72. Goossens GH, Jocken JWE, Blaak EE, et al. Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: effect of p-adre-nergic stimulation. Hypertension 2007; 49:542-547.
73. Koopman R, van Loon LJ. Aging, exercise and muscle protein metabolism. J Appl Physiol 2009; 106:2040-2048.
74. Rennie MJ. Anabolic resistance: the effects of aging, sexual dimorphism, and immobilization on human muscle protein turnover. Appl Physiol Nutr Metab 2009; 34:377-381.
75. Cuthbertson D, Smith K, Babraj J, et al. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J 2005; 19:422-424.
76. Greenhaff PL, Karagounis LG, Peirce N, et al. Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 2008; 295:E595-604.
77. Fujita S, Rasmussen BB, Cadenas JG, et al. The effect of insulin on human skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood flow and amino acid availability. Am J Physiol Endocrinol Metab 2006; 291:E745-E754.
78. Rasmussen BB, Fujita S, Wolfe RR, et al. Insulin resistance of muscle protein metabolism in aging. FASEB J 2006; 20:768-769.
79. Ryall JG, Sillence MN, Lynch GS. Systemic administration of p2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br J Pharmacol 2006; 147:587-595.
80. 2+-ATPase protein and activity. Am J Physiol Heart Circ Physiol 2008; 294:H2587-H2595
81. Molenaar P, Chen L, Parsonage WA. Cardiac implications for the use of p2-adrenoceptor agonists for the management of muscle wasting. Br J Pharma col 2006; 147:583-586.